|
|
|
| Clinical Efficacy of Glutamine Combined with Erythropoietin in the Treatment of Necrotizing Enterocolitis in Premature Infants and Its Effect on Serum IL-6 TNF-α and i-FABP Levels |
| SUN Shiqi, PIAO Qian |
| The First Affiliated Hospital of China Medical University, Liaoning Shenyang 110001, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy of glutamine combined with erythropoietin in the treatment of necrotizing enterocolitis (NEC) in premature infants and its effect on serum IL-6, TNF-α, and i-FABP levels. Methods: A retrospective analysis was conducted on 100 premature infants diagnosed with NEC in the Department of Neonatology, The First Affiliated Hospital of China Medical University from January 2020 to January 2022. According to the treatment methods received by the infants, they were divided into the observation group (n=50) and the control group (n=50). The observation group was treated with glutamine combined with erythropoietin, and the control group was treated with glutamine alone. The total effective rate, inflammatory reaction, i-FABP, immunoglobulin level, intestinal flora change, and drug safety of the two groups were recorded and observed. Results: The total effective rate of the observation group (92.00%) was significantly higher than that of the control group (70.00%), and the difference was statistically significant (P<0.05). Before treatment, there was no statistically significant difference in the levels of serum inflammatory factors, i-FABP, IgA, IgM, IgG, and the total number of bacteria, cocci, and bacilli in the stool specimens between the two groups (P>0.05). Compared with before treatment, the levels of serum IL-6, TNF-α and i-FABP in both groups decreased after 7 days of treatment, and the levels of IgA, IgM, IgG, the total number of bacteria, cocci, and bacilli in the stool specimens increased. The differences were statistically significant (P<0.05). There was a statistically significant difference in the changes of serum IL-6, TNF-α, i-FABP, IgA, IgM, IgG levels, and the total number of bacteria, cocci, and bacilli in the stool specimens before and after treatment between the two groups (P<0.05). During the one-month follow-up, there was no statistically significant difference in the adverse reactions between the two groups (P>0.05). Conclusion: On the basis of glutamine, combined erythropoietin can effectively improve the clinical efficacy of NEC in premature infants, reduce the levels of serum inflammatory factors and i-FABP, promote the stability of intestinal flora in premature infants, enhance the immunity of infants, and has a high safety.
|
|
|
|
|
|
[1] 王娟,粱宽.新生儿坏死性小肠结肠炎不良预后的危险因素及其预测价值[J].海南医学,2022,33(23):3049-3052.
[2] 张国敬.谷氨酰胺治疗新生儿坏死性小肠结肠炎机制的研究进展[J].天津医科大学学报,2021,27(2):191-194.
[3] 王欢.促红细胞生成素在新生儿坏死性小肠结肠炎防治中的研究进展[J].儿科药学杂志,2020,26(1):60-64.
[4] 王卫平,孙坤,常立文.儿科学(第9版全国医学院校本科临床西医教材)[M].北京:人民卫生出版社.2018.213-236.
[5] 李佳美,梁会营.近10年早产儿坏死性小肠结肠炎文献计量分析[J].中国现代医生,2022,60(31):73-77.
[6] 许萍萍.早产儿的临床流行病学调查[D].河北:河北医科大学,2016.
[7] 郭建明,李菁,陶荔,等.谷氨酰胺预防新生儿坏死性小肠结肠炎临床分析[J].江西医药,2019,54(7):801-802.
[8] Dilaiz A,Ciftci I I,Aktan TM,et al.Enteral glutamine supplementation and dexamethasone attenuate the local intestinal damage in rats with experimental necrotizing enterocolitis[J].Pediatric surgery international,2003,19(8):578-582.
[9] 林志龙.丙酮酸盐对大鼠小肠缺血再灌注引起的肠屏障损伤的保护作用及机制的研究[D].石家庄:河北医科大学,2013.
[10] 傅晓燕,谢晓恬.促红细胞生成素的早产儿临床应用研究进展[J].世界临床药物,2020,41(3):172-176,198. |
|
|
|
2024, Vol. 30 
